Please assess the completion status of the following clinical trial:

Trial Title: Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All subjects:~* HIV antibody seronegative (negative HIV rapid test),~* 18 years or older,~* Has a smart phone with access to two-way video call capability,~* Willingness to be contacted for a short call every day for 4 weeks,~* Adequate renal function (creatinine clearance ≥ 60 ml/min estimated by the Cockcroft Creatinine Clearance Formula),~* Provides written informed consent,~For Transgender women:~* Male assigned sex at birth, and self-reported current gender identity as woman or transgender women, or other trans-feminine spectrum identity,~* Current feminizing Hormone Therapy (HT) use for at least 6 months,~For Transgender men:~* Female assigned sex at birth, and self-reported current gender identity as man or transgender man, or other trans-masculine spectrum identity,~* Current masculinizing Hormone Therapy (HT) use for at least 6 months with testosterone~Exclusion Criteria~* Expects to change or discontinue current HT use during the 4 weeks study period,~* Signs of symptoms of acute viral syndrome,~* Use of FTC or TDF in the past 90 days~* Receiving ongoing therapy with any of the following:~AntiRetroviral Therapy, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents~* Renal insufficiency documented as Creatinine Clearance \< 60 ml/min~* For masculine-spectrum identifying persons, positive pregnancy test at screening~* At enrollment, has any other condition or factor that, based on the opinion of the investigator or designee, would preclude provision of informed consent; make participation in the study unsafe; complicate interpretation of study outcome data; or otherwise interfere with achieving the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- TRUVADA DOT (Type: EXPERIMENTAL): one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).